NEW YORK (dpa-AFX Broker) - US bank JPMorgan has doubled its price target for Bayer from €25 to €50 and upgraded the shares from "neutral" to "overweight." The Leverkusen-based company's shares are among analyst Richard Vosser's industry favorites, alongside AstraZeneca and Novartis, as he wrote on Monday in his outlook for 2026 for the European pharmaceutical industry. Bayer's business situation is improving and, on top of that, there is a chance that the negative consequences of the glyphosate litigation will be mitigated. /ag/bek
Publication of the original study: 08.12.2025 / 03:11 / GMT
First disclosure of the original study: 08.12.2025 / 03:14 / GMT
-----------------------
dpa-AFX Broker – trader news from dpa-AFX
-----------------------
